Suppr超能文献

重症肌无力患者胸腺切除术后 II 型纤维萎缩:类固醇诱导的改变具有预后意义。

Atrophy of type II fibres in myasthenia gravis muscle in thymectomized patients: steroid-induced change with prognostic impact.

机构信息

Department of Pathology and Molecular Medicine, Charles University, 2nd Medical Faculty and University Hospital Motol, Prague, Czech Republic.

1st Department of Infectious Diseases, Charles University, 2nd Medical Faculty and University Hospital Bulovka, Czech Republic.

出版信息

J Cell Mol Med. 2009 Aug;13(8B):2008-2018. doi: 10.1111/j.1582-4934.2008.00431.x. Epub 2008 Jul 24.

Abstract

Selective atrophy of type II muscle fibres has been long recognized as an enigmatic but consistent feature of myasthenia gravis (MG) muscle; however, the pathophysiology and the mechanism of that change have remained obscure. In the present study, the results of histomorphometric analysis performed on muscle biopsies from 207 thymectomized seropositive MG patients were correlated with clinical features of MG to demonstrate possible pathophysiological associations and potential prognostic impact. The atrophy of type II fibres was verified in 35 cases (16.9%), being more pronounced in fibres of IIB subtype. It was neither significantly associated with the duration and severity of MG nor with the age of the patients. On the other hand, we demonstrated that the atrophy associated with long-term treatment with corticosteroids, and correlated with increasing doses. Thus, we suppose that the atrophy of type II muscle fibres in seropositive MG is steroid induced rather than MG-associated event. Although the MG patients with atrophy of type II fibres did not differ from the remaining MG cases in terms of improvement in the disease during the follow-up period, our analysis provides clear evidence that they presented a significantly slower tendency to reach an asymptomatic state after thymectomy. Therefore, the steroid-induced atrophy of type II fibres in MG muscle might be considered to be an unfavourable prognostic factor.

摘要

II 型肌纤维选择性萎缩一直被认为是重症肌无力(MG)肌肉的一个神秘但一致的特征;然而,其变化的病理生理学和机制仍不清楚。在本研究中,对 207 例胸腺瘤阳性 MG 患者的肌肉活检进行组织形态计量学分析的结果与 MG 的临床特征相关联,以证明可能的病理生理学关联和潜在的预后影响。在 35 例(16.9%)中验证了 II 型纤维的萎缩,在 IIB 亚型的纤维中更为明显。它与 MG 的持续时间和严重程度或患者的年龄均无显著相关性。另一方面,我们证明与长期皮质类固醇治疗相关的萎缩与剂量增加相关。因此,我们假设胸腺瘤阳性 MG 中的 II 型肌纤维萎缩是类固醇诱导的,而不是与 MG 相关的事件。尽管在随访期间,II 型纤维萎缩的 MG 患者在疾病改善方面与其余 MG 病例没有差异,但我们的分析提供了明确的证据表明,他们在胸腺切除术后达到无症状状态的趋势明显较慢。因此,MG 肌肉中类固醇诱导的 II 型纤维萎缩可能被认为是一个不利的预后因素。

相似文献

1
Atrophy of type II fibres in myasthenia gravis muscle in thymectomized patients: steroid-induced change with prognostic impact.
J Cell Mol Med. 2009 Aug;13(8B):2008-2018. doi: 10.1111/j.1582-4934.2008.00431.x. Epub 2008 Jul 24.
2
Neurogenic muscle involvement in myasthenia gravis. A clinical and histopathological study.
J Neurol Neurosurg Psychiatry. 1973 Apr;36(2):244-54. doi: 10.1136/jnnp.36.2.244.
3
Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis.
Eur J Neurol. 2002 Jan;9(1):55-61. doi: 10.1046/j.1468-1331.2002.00352.x.
4
Neurogenic muscle atrophy in myasthenia gravis.
J Neurol Neurosurg Psychiatry. 1972 Jun;35(3):311-22. doi: 10.1136/jnnp.35.3.311.
5
[Thymectomy in the treatment of myasthenia gravis].
Zhonghua Yi Xue Za Zhi. 1998 May;78(5):363-5.
7
Maximal thymectomy for myasthenia gravis.
Eur J Cardiothorac Surg. 1995;9(8):461-4. doi: 10.1016/s1010-7940(05)80083-1.
9
MRI evidence of early muscle atrophy in MuSK positive myasthenia gravis.
J Neuroimaging. 2011 Jul;21(3):303-5. doi: 10.1111/j.1552-6569.2009.00456.x. Epub 2009 Dec 4.
10
[Thymectomy in Chinese myasthenia gravis].
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1987 Feb;20(1):15-22.

引用本文的文献

1
Rituximab for myasthenia gravis.
Cochrane Database Syst Rev. 2025 Jul 3;7(7):CD014574. doi: 10.1002/14651858.CD014574.pub2.
2
IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis.
Acta Neuropathol Commun. 2015 Jan 15;3:1. doi: 10.1186/s40478-014-0179-6.

本文引用的文献

1
Neurologic outcomes of thymectomy in myasthenia gravis: comparative analysis of the effect of thymoma.
J Thorac Cardiovasc Surg. 2007 Sep;134(3):601-7. doi: 10.1016/j.jtcvs.2007.05.015.
2
Muscle lymphocytic infiltrates in thymoma-associated myasthenia gravis are phenotypically different from those in polymyositis.
Neuromuscul Disord. 2007 Dec;17(11-12):935-42. doi: 10.1016/j.nmd.2007.05.010. Epub 2007 Jul 24.
3
Myasthenia gravis presenting with unusual neurogenic muscle atrophy.
Muscle Nerve. 2007 Sep;36(3):394-9. doi: 10.1002/mus.20757.
4
The effectiveness of thymectomy on seronegative generalized myasthenia gravis: comparing with seropositive cases.
Acta Neurol Scand. 2007 Mar;115(3):181-4. doi: 10.1111/j.1600-0404.2006.00733.x.
5
Major pathogenic effects of anti-MuSK antibodies in myasthenia gravis.
J Neuroimmunol. 2006 Aug;177(1-2):119-31. doi: 10.1016/j.jneuroim.2006.05.017. Epub 2006 Jul 20.
6
MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo.
J Neuroimmunol. 2005 Dec 30;170(1-2):41-8. doi: 10.1016/j.jneuroim.2005.08.016. Epub 2005 Oct 6.
7
Skeletal muscle hypertrophy and atrophy signaling pathways.
Int J Biochem Cell Biol. 2005 Oct;37(10):1974-84. doi: 10.1016/j.biocel.2005.04.018.
8
Factors influencing the outcome of transsternal thymectomy for myasthenia gravis.
Acta Neurol Scand. 2005 Aug;112(2):108-14. doi: 10.1111/j.1600-0404.2005.00424.x.
10
Myasthenia gravis: clinical, immunological, and therapeutic advances.
Acta Neurol Scand. 2005 Feb;111(2):134-41. doi: 10.1111/j.1600-0404.2005.00374.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验